Hereditary Angioedema Market, by Drug Class, Route of Administration, Distribution Channel, and Region - Global Trends and Forecast, 2022 - 2028

Hereditary Angioedema Market, by Drug Class, Route of Administration, Distribution Channel, and Region - Global Trends and Forecast, 2022 - 2028

Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The disease causes swelling particularly of the face and airways and abdominal cramping. The World Allergy Organization (WAO) has set out guidelines to use the different class of drugs such as esterase inhibitors, kallikrein inhibitors and other drugs approved to treat hereditary angioedema.
Market Dynamics
The major factor driving growth of the hereditary angioedema market include intense R&D initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the presence of promising drug pipeline. For instance, in 2021, Attune Pharmaceuticals, revealed the successful study results the first preclinical data results for ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE). Also, the approval of novel therapies by the regulatory agencies is expected to be a factor augmenting market growth. For instance, in 2014, the FDA approved Ruconest manufactured by Pharming Healthcare, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE. However, lack of awareness regarding the diseases, inefficient diagnosis and high cost of drugs are the factors restraining hereditary angioedema market growth.
Key features of the study:

This report provides in-depth analysis of hereditary angioedema market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global hereditary angioedema market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include CSL Behring, Shire Plc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Adverum Biotechnologies, Attune Pharmaceuticals and Pharming Healthcare, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology upgrade, market expansion, and marketing tactics
The global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pet cancer therapeutics market

Detailed Segmentation:

Global Hereditary Angioedema Market, By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

Global Hereditary Angioedema Market, By Route of Administration:

Subcutaneous
Intravenous
Oral

Global Hereditary Angioedema Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

Global Hereditary Angioedema Market, By Geography:

North America

By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

By Route of Administration:

Subcutaneous
Intravenous
Oral

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

U.S.
Canada

Latin America

By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

By Route of Administration:

Subcutaneous
Intravenous
Oral

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Europe

By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

By Route of Administration:

Subcutaneous
Intravenous
Oral

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific

By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

By Route of Administration:

Subcutaneous
Intravenous
Oral

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East

By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

By Route of Administration:

Subcutaneous
Intravenous
Oral

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

GCC
Israel
Rest of Middle East

Africa

By Drug Class:

C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others

By Route of Administration:

Subcutaneous
Intravenous
Oral

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Country:

South Africa
Central Africa
North Africa

Company Profiles

CSL Behring*

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments

Shire Plc.
Pharming Healthcare, Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Attune Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.